ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 294,37
-1,22%
Dow Jones
42 515,98
0,45%
DAX
19 969,86
-1,44%
Brent Oil
72,455
-0,38%
Bitcoin
96 270,12
-3,81%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Mirum Pharmaceuticals Inc (MIRM)

  7. Mirum Pharmaceuticals Inc (MIRM) Actualités

MIRM

Mirum Pharmaceuticals (MIRM)

Mirum Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MIRM
DateHeureSourceTitreSymboleSociété
11/12/202400h00Business WireMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MIRMMirum Pharmaceuticals Inc
15/11/202423h34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MIRMMirum Pharmaceuticals Inc
14/11/202414h00Business WireMirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver MeetingNASDAQ:MIRMMirum Pharmaceuticals Inc
12/11/202417h44Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:MIRMMirum Pharmaceuticals Inc
12/11/202414h14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MIRMMirum Pharmaceuticals Inc
12/11/202414h00Business WireMirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:MIRMMirum Pharmaceuticals Inc
07/11/202422h30Business WireMirum Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:MIRMMirum Pharmaceuticals Inc
04/11/202422h30Business WireMirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024NASDAQ:MIRMMirum Pharmaceuticals Inc
31/10/202413h30Business WireMirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual MeetingNASDAQ:MIRMMirum Pharmaceuticals Inc
10/10/202414h30Business WireVolixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary CholangitisNASDAQ:MIRMMirum Pharmaceuticals Inc
07/08/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRMMirum Pharmaceuticals Inc
07/08/202422h01Business WireMirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:MIRMMirum Pharmaceuticals Inc
31/07/202422h30Business WireMirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024NASDAQ:MIRMMirum Pharmaceuticals Inc
25/07/202414h30Business WireMirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and OlderNASDAQ:MIRMMirum Pharmaceuticals Inc
08/07/202422h46Business WireApprobation du LIVMARLI de Mirum Pharmaceuticals dans l'Union européenne pour les patients atteints de PFICNASDAQ:MIRMMirum Pharmaceuticals Inc
08/07/202422h20Business WireLIVMARLI von Mirum Pharmaceuticals wird in der Europäischen Union für Patienten mit PFIC zugelassenNASDAQ:MIRMMirum Pharmaceuticals Inc
08/07/202414h30Business WireMirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFICNASDAQ:MIRMMirum Pharmaceuticals Inc
28/06/202414h30Business WireMirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTXNASDAQ:MIRMMirum Pharmaceuticals Inc
17/06/202414h00Business WireMirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC StudiesNASDAQ:MIRMMirum Pharmaceuticals Inc
16/06/202423h00Business WireMirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024NASDAQ:MIRMMirum Pharmaceuticals Inc
07/06/202406h04Business WireLangfristige Daten aus den LIVMARLI-Studien von Mirum bei ALGS und PFIC auf dem EASL-Kongress vorgestelltNASDAQ:MIRMMirum Pharmaceuticals Inc
07/06/202406h04Business WireLes données à long terme des études LIVMARLI de Mirum sur l’ALGS et la PFIC présentées au congrès de l’EASLNASDAQ:MIRMMirum Pharmaceuticals Inc
06/06/202415h30Business WireLong-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL CongressNASDAQ:MIRMMirum Pharmaceuticals Inc
05/06/202422h05Business WireMirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:MIRMMirum Pharmaceuticals Inc
31/05/202423h02Business WireMirum Pharmaceuticals: positive CHMP-Stellungnahme für LIVMARLI® (Maralixibat) als orale Lösung zur Behandlung von PFIC bei Patienten ab einem Alter von drei MonatenNASDAQ:MIRMMirum Pharmaceuticals Inc
31/05/202419h12Business WireMirum Pharmaceuticals annonce un avis favorable du CHMP pour la solution orale LIVMARLI® (maralixibat) dans le traitement des patients atteints de CIFP âgés de trois mois et plusNASDAQ:MIRMMirum Pharmaceuticals Inc
31/05/202414h30Business WireMirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and OlderNASDAQ:MIRMMirum Pharmaceuticals Inc
29/05/202414h30Business WireLong-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL CongressNASDAQ:MIRMMirum Pharmaceuticals Inc
18/05/202413h00Business WireMirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual MeetingNASDAQ:MIRMMirum Pharmaceuticals Inc
08/05/202422h02Business WireMirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:MIRMMirum Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MIRM

Dernières Valeurs Consultées

SPI
SP500
S&P 500
NASDAQ
MSFT
Microsoft
USI
USTECH100
US Tech 100
NYSE
JPM
JP Morgan Chase
EU
PX4
SBF 120
EU
HO
Thales
EU
VIV
Vivendi
EU
SGO
Cie de SaintGobain
EU
VK
Vallourec
COIN
ETHUSD
Ethereum
EU
BNP
BNP Paribas
EU
CAP
Capgemini
EU
AI
Air Liquide
EU
BEL20
Bel 20
NASDAQ
AAPL
Apple
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés